Experimental immune therapy tested for Tough-to-Treat blood cancer
NCT ID NCT04322292
Summary
This small, early-stage study tested a new type of personalized immune therapy called C-CAR088 in patients whose multiple myeloma had returned or stopped responding to standard treatments. Doctors collected and genetically modified each patient's own T-cells to target a protein (BCMA) on the cancer cells, then infused them back. The main goal was to check if this approach was safe and to look for early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
InstituteHBDH
Tianjin, 300000, China
Conditions
Explore the condition pages connected to this study.